Paul J. Hastings
Known title: DirectorCIK: 0001309702
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Transaction History
| NKTX | ▼ Sell | Open Market | 1,776 | $5K | 6/18/2026 | View on chart |
| NKTX | ▼ Sell | Open Market | 26,046 | $54K | 1/15/2026 | View on chart |
| NKTX | ▲ Buy | Grant | 94,000 | $0 | 1/6/2026 | View on chart |
| NKTX | ▼ Sell | Open Market | 1,790 | $3K | 6/18/2025 | View on chart |
| NKTX | ▼ Sell | Open Market | 17,378 | $38K | 1/15/2025 | View on chart |
| NKTX | ▲ Buy | Grant | 94,500 | $0 | 1/3/2025 | View on chart |
| NKTX | ▼ Sell | Open Market | 1,770 | $10K | 6/18/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 880 | $25K | 6/13/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 5,230 | $0 | 6/12/2024 | View on chart |
| NKTX | ▼ Sell | Other | 137,642 | $1.8M | 3/4/2024 | View on chart |
| NKTX | ▼ Sell | Other | 12,358 | $161K | 3/1/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 9,697 | $85K | 1/16/2024 | View on chart |
| NKTX | ▲ Buy | Grant | 85,000 | $0 | 1/4/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 1,704 | $8K | 6/20/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 1,775 | $0 | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 580 | $22K | 6/5/2023 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 7,000 | $209K | 5/15/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 7,000 | $293K | 5/15/2023 | View on chart |
| NKTX | ▼ Sell | Open Market | 3,691 | $20K | 1/17/2023 | View on chart |
| NKTX | ▲ Buy | Grant | 64,500 | $0 | 1/13/2023 | View on chart |
| NKTX | ▼ Sell | Open Market | 498 | $6K | 9/29/2022 | View on chart |
| NKTX | ▼ Sell | Open Market | 23,376 | $305K | 9/28/2022 | View on chart |
| NKTX | ▼ Sell | Open Market | 6,126 | $80K | 9/21/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 533 | $30K | 7/11/2022 | View on chart |
| NKTX | ▲ Buy | Grant | 19,500 | $0 | 6/17/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 1,160 | $0 | 6/8/2022 | View on chart |
| NKTX | ▲ Buy | Grant | 41,900 | $0 | 1/14/2022 | View on chart |
| NKTX | ▼ Sell | Open Market | 8,277 | $225K | 9/29/2021 | View on chart |
| NKTX | ▼ Sell | Open Market | 223 | $6K | 9/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress
Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress. Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.